Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: ABT stock price vs NTRA: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at NTRA's multiple
Needs NTRA P/E.
Implied fair value · at ABT's multiple
Needs Annual EPS is negative, ABT P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ABBOTT LABORATORIES · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
NATERA, INC. · implied price per share
At least 3 of the last 5 annual free-cash-flow observations must be positive.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Johnson & Johnson
ABT vs JNJ
Medtronic plc
ABT vs MDT
BECTON DICKINSON & CO
ABT vs BDX
Thermo Fisher Scientific Inc.
ABT vs TMO
DANAHER CORP /DE/
ABT vs DHR
BOSTON SCIENTIFIC CORP
ABT vs BSX
ILLUMINA, INC.
ABT vs ILMN
EXACT SCIENCES CORP
ABT vs EXAS
AMGEN INC
ABT vs AMGN
VERTEX PHARMACEUTICALS INC / MA
ABT vs VRTX
REGENERON PHARMACEUTICALS, INC.
ABT vs REGN
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe ABT should be valued more like a mature, profitable healthcare company than a high-growth loss-making NTRA like NTRA, then avoid relying on the $420.42 P/S-implied upside and instead anchor on ABT’s historical band and DCF range, because ABT’s operating quality is strong but its current price is already above DCF and near its recent trading range.
ABT trades at $107.96 versus an implied price of $420.42 from the P/S comparison, suggesting a very large apparent upside of 289.4%. However, that gap is not supported by ABT’s own valuation context, since its current price is already within the $97.16 to $118.76 historical band and far above the $50.11 to $67.80 DCF range.
Supporting Metrics
